293 related articles for article (PubMed ID: 32142668)
1. Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Fortin J; Tian R; Zarrabi I; Hill G; Williams E; Sanchez-Duffhues G; Thorikay M; Ramachandran P; Siddaway R; Wong JF; Wu A; Apuzzo LN; Haight J; You-Ten A; Snow BE; Wakeham A; Goldhamer DJ; Schramek D; Bullock AN; Dijke PT; Hawkins C; Mak TW
Cancer Cell; 2020 Mar; 37(3):308-323.e12. PubMed ID: 32142668
[TBL] [Abstract][Full Text] [Related]
2. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
Hoeman CM; Cordero FJ; Hu G; Misuraca K; Romero MM; Cardona HJ; Nazarian J; Hashizume R; McLendon R; Yu P; Procissi D; Gadd S; Becher OJ
Nat Commun; 2019 Mar; 10(1):1023. PubMed ID: 30833574
[TBL] [Abstract][Full Text] [Related]
3. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.
Buczkowicz P; Hoeman C; Rakopoulos P; Pajovic S; Letourneau L; Dzamba M; Morrison A; Lewis P; Bouffet E; Bartels U; Zuccaro J; Agnihotri S; Ryall S; Barszczyk M; Chornenkyy Y; Bourgey M; Bourque G; Montpetit A; Cordero F; Castelo-Branco P; Mangerel J; Tabori U; Ho KC; Huang A; Taylor KR; Mackay A; Bendel AE; Nazarian J; Fangusaro JR; Karajannis MA; Zagzag D; Foreman NK; Donson A; Hegert JV; Smith A; Chan J; Lafay-Cousin L; Dunn S; Hukin J; Dunham C; Scheinemann K; Michaud J; Zelcer S; Ramsay D; Cain J; Brennan C; Souweidane MM; Jones C; Allis CD; Brudno M; Becher O; Hawkins C
Nat Genet; 2014 May; 46(5):451-6. PubMed ID: 24705254
[TBL] [Abstract][Full Text] [Related]
6. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.
Nikbakht H; Panditharatna E; Mikael LG; Li R; Gayden T; Osmond M; Ho CY; Kambhampati M; Hwang EI; Faury D; Siu A; Papillon-Cavanagh S; Bechet D; Ligon KL; Ellezam B; Ingram WJ; Stinson C; Moore AS; Warren KE; Karamchandani J; Packer RJ; Jabado N; Majewski J; Nazarian J
Nat Commun; 2016 Apr; 7():11185. PubMed ID: 27048880
[TBL] [Abstract][Full Text] [Related]
7. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
[TBL] [Abstract][Full Text] [Related]
8. ACVR1 Function in Health and Disease.
Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
[No Abstract] [Full Text] [Related]
9. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
10. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
11. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
Buczkowicz P; Bartels U; Bouffet E; Becher O; Hawkins C
Acta Neuropathol; 2014 Oct; 128(4):573-81. PubMed ID: 25047029
[TBL] [Abstract][Full Text] [Related]
12. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
Han HJ; Jain P; Resnick AC
Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
[TBL] [Abstract][Full Text] [Related]
13. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
14. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
Pacifici M; Shore EM
Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
[TBL] [Abstract][Full Text] [Related]
15. Repurposing Vandetanib plus Everolimus for the Treatment of
Carvalho DM; Richardson PJ; Olaciregui N; Stankunaite R; Lavarino C; Molinari V; Corley EA; Smith DP; Ruddle R; Donovan A; Pal A; Raynaud FI; Temelso S; Mackay A; Overington JP; Phelan A; Sheppard D; Mackinnon A; Zebian B; Al-Sarraj S; Merve A; Pryce J; Grill J; Hubank M; Cruz O; Morales La Madrid A; Mueller S; Carcaboso AM; Carceller F; Jones C
Cancer Discov; 2022 Feb; 12(2):416-431. PubMed ID: 34551970
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
[TBL] [Abstract][Full Text] [Related]
17. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
18. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
19. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
[TBL] [Abstract][Full Text] [Related]
20. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
